TRVI Share Price Performance
US$13.30
9.00 (209.30%)
50.7% undervalued intrinsic discount
US$27.00
Fair Value
Price US$13.30
AnalystHighTarget US$27.00
Fair ValueUS$27.00
Share Pricen/a
Trevi Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
TRVI Community Narratives
AN
Fair Value US$27 50.7% undervalued intrinsic discount
Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential
Catalysts About Trevi Therapeutics Trevi Therapeutics is a clinical stage biopharmaceutical company developing Haduvio, an extended release formulation of nalbuphine, for multiple chronic cough indications where there are currently no FDA approved therapies. What are the underlying business or industry changes driving this perspective?Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$27
50.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
60.12%
Future PE
25.8x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Chronic Cough Platform And Strong Cash Runway Will Support Future Upside Potential
Fair Value: US$27 50.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Trevi Therapeutics, Inc. Key Details
About TRVI
- Founded
- 2011
- Employees
- 34
- CEO
- WebsiteView website
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in patients with pruritus; and phase 2b/3 clinical trial in patients with prurigo nodularis. Trevi Therapeutics, Inc. has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
